Justin Klee's guest appearances

Justin Klee

Generation Bold

Adriane Berg: Generation Bold--The Fountain of Truth About Aging--Health, Wealth, Science, Success

Sue Johansen

Diana Nyad

Jason Miller

Louise Aronson

Ken Rubin

Aubrey de Grey

Allana Pratt

Peter Anderson

Esther Dyson

Timothy Jennings

Josh Cohen

Martha Orellana

Ali Sareea

Chris Nall

Robin Fenley

OwlTail

Josh Cohen, Co-CEO and Co-FounderJoshua Cohen co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its co-CEO. Josh has overseen the growth of Amylyx from a dorm-room concept to a clinical stage pharmaceutical company. His research experience includes work both at Brown University and at the National Institute of Standards in Technology. Josh received his BS in biomedical engineering from Brown University.Justin Klee, Co-CEO and Co-FounderJustin Klee co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its co-CEO. Along with his co-founder Josh, Justin has overseen the development of Amylyx’s novel platform and therapeutic for neurodegenerative diseases from initial testing through clinical trials. Justin previously did research at Brown University in neural systems and neurophysiology and Alzheimer’s disease at Harvard Medical School. He received his Sc.B in Neuroscience from Brown University.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/3240049/advertisement

Josh Cohen, Co-CEO and Co-Founder Joshua Cohen co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its co-CEO. Josh has overseen the growth of Amylyx from a dorm-room concept to a clinical stage pharmaceutical company. His research experience includes work both at Brown University and at the National Institute of Standards in Technology. Josh received his BS in biomedical engineering from Brown University. Justin Klee, Co-CEO and Co-Founder Justin Klee co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its co-CEO. Along with his co-founder Josh, Justin has overseen the development of Amylyx’s novel platform and therapeutic for neurodegenerative diseases from initial testing through clinical trials. Justin previously did research at Brown University in neural systems and neurophysiology and Alzheimer’s disease at Harvard Medical School. He received his Sc.B in Neuroscience from Brown University. This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at <a href="https://www.spreaker.com/show/3240049/advertisement" rel="nofollow" target="_blank">https://www.spreaker.com/show/3240049/advertisement</a>

Generation Bold Radio, June 7, 2020--Guests: Josh Cohen & Justin Klee, Amylyx Pharmaceuticals

Josh Cohen, Co-CEO and Co-Founder Joshua Cohen co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its co-CEO. Josh has overseen the growth of Amylyx from a dorm-room concept to a clinical stage pharmaceutical company. His research experience includes work both at Brown University and at the National Institute of Standards in Technology. Josh received his BS in biomedical engineering from Brown University. Justin Klee, Co-CEO and Co-Founder Justin Klee co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its co-CEO. Along with his co-founder Josh, Justin has overseen the development of Amylyx’s novel platform and therapeutic for neurodegenerative diseases from initial testing through clinical trials. Justin previously did research at Brown University in neural systems and neurophysiology and Alzheimer’s disease at Harvard Medical School. He received his Sc.B in Neuroscience from Brown University.

Josh Cohen, Co-CEO and Co-Founder Joshua Cohen co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its co-CEO. Josh has overseen the growth of Amylyx from a dorm-room concept to a clinical stage pharmaceutical company. His research experience includes work both at Brown University and at the National Institute of Standards in Technology. Josh received his BS in biomedical engineering from Brown University. Justin Klee, Co-CEO and Co-Founder Justin Klee co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its co-CEO. Along with his co-founder Josh, Justin has overseen the development of Amylyx’s novel platform and therapeutic for neurodegenerative diseases from initial testing through clinical trials. Justin previously did research at Brown University in neural systems and neurophysiology and Alzheimer’s disease at Harvard Medical School. He received his Sc.B in Neuroscience from Brown University.